Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 2008, p. 1577-1579, Vol. 52, No. 4
0066-4804/08/$08.00+0 doi:10.1128/AAC.01023-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Killing of Neisseria gonorrhoeae, Streptococcus agalactiae (Group B Streptococcus), Haemophilus ducreyi, and Vaginal Lactobacillus by 3-O-Octyl-sn-Glycerol
B. J. Moncla,1,2*
K. Pryke,2 and
Charles E. Isaacs3
Department of Obstetrics, Gynecology and Reproductive Sciences,1
Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, Pennsylvania,2
New York State Institute for Basic Research in Developmental Disabilities, Department of Developmental Biochemistry, Staten Island, New York3
Received 3 August 2007/
Returned for modification 21 September 2007/
Accepted 22 January 2008

ABSTRACT
The microbicide candidate octylglycerol inactivates sexually
transmitted bacterial pathogens at concentrations which spare
normal vaginal flora (lactobacillus). Standard minimum microbicidal
concentration assays and time-kill assays revealed the drug
concentrations and times required for inactivation. Octylglycerol
concentrations must exceed the binding capacity of any human
serum albumin to be effective.

TEXT
Octylglycerol (OG) is an antimicrobial lipid currently being
evaluated as a vaginal microbicide to reduce the transmission
of human immunodeficiency virus and other sexually transmitted
infections (STIs). It is similar in activity to antimicrobial
lipids naturally occurring in human milk (
5). Its efficacy against
human immunodeficiency virus and herpes simplex virus has been
demonstrated (
3-
6). Ideally, vaginal microbicides should not
have deleterious effects on the normal vaginal flora such as
H
2O
2-producing
Lactobacillus spp. while killing pathogens. We
therefore tested the activity of 1-
O-octyl-
sn-glycerol (1-OG)
and 3-OG (Fig.
1) against
Neisseria gonorrhoeae, Haemophilus ducreyi, group B streptococci, and
Lactobacillus species. 3-OG
is much less expensive to synthesize than 1-OG, and therefore
most of these studies were done with 3-OG. 3-OG was obtained
from Genzyme (Cambridge, MA; lot number 6234). 1-OG was synthesized
in C. E. Isaacs's laboratory.
The minimum microbicidal concentration (MCC) assay is the current
standard to determine the minimum concentration of drug required
to kill 99.99% of the test organisms in 30 min. Relevant organisms
were studied using the assay exactly as described in the literature
(
6,
8), with the exception that we used ACES [
N-(2-acetamido)-2-aminoethanesulfonic
acid] in place of RPMI 1640 as our medium as described previously
(
8). Bacterial reference strains were obtained from the American
Type Culture Collection (ATCC) (Manassas, VA). Field isolates
were obtained from human vaginal samples and identified to the
species level as described previously (
8). Organisms were stored
frozen at –70°C in litmus milk until needed and revived
by plating onto either blood agar plates (Columbia blood agar
base for
Lactobacillus and
Streptococcus; PML Microbiologicals,
Wilsonville, OR) or chocolate agar (PML Microbiologicals or
prepared in house) for
Neisseria gonorrhoeae. Haemophilus ducreyi isolates, kindly provided by P. Totten, University of Washington,
Seattle, were cultured and stored as described for
N. gonorrhoeae.
All cultures were incubated at 35°C in air enriched to 6%
CO
2 overnight or until good growth was observed.
Pseudomonas aeruginosa was cultured as described for
Lactobacillus.
As demonstrated in Table 1, N. gonorrhoeae and H. ducreyi had lower MCCs than the other organisms tested. MCCs of the strains tested with both 1-OG and 3-OG were comparable, but the 1-OG MCCs demonstrated narrower ranges (Table 1). Representative Lactobacillus vaginalis strains were found to be resistant to killing by the highest concentration tested, 50 mM (Table 1).
The presence of serum and whole blood reduced the microbicidal
activity of OG and other microbicide candidates screened (data
not shown). Albumin, the major serum protein, has well-characterized
fatty acid binding sites; therefore, we examined bacterial killing
in the presence of human serum albumin (HSA). Killing was reduced
partially or completely, depending upon the ratio of HSA to
OG. In order to estimate the binding of 3-OG to HSA, MCCs were
determined in the presence of different concentrations of HSA.
The changes in the apparent MCCs were used to estimate the quantity
of free OG. Assays of MCCs without HSA were performed concurrently
with each experiment, as outlined above. HSA and "essential-fatty-acid-free"
HSA were obtained from Sigma Chemical Co. (1
x crystallized and
lyophilized; product numbers A9511 and A3782; essentially globulin
and fatty acid free). For use, 10% (wt/vol) solutions were prepared
in ACES buffer, filter sterilized, and stored at 4°C until
used (up to 1 week). ACES buffer was used at a pH of 7.2 with
an isotonic strength adjusted to 200 to 300 mosmol/kg (
8). The
concentration of free OG was estimated assuming different numbers
of OG binding sites on the HSA. Using the MCCs for the organisms
tested suggested a six-binding-site model (Table
2). Using delipidated
HSA resulted in greater protection from killing (Table
3).
P. aeruginosa was used to demonstrate that the effect of HSA is
a general phenomenon and not just interaction with vaginal organisms.
An effective microbicide for STI prevention must kill the pathogens
in 30 min or less of exposure. In order to demonstrate the rapidity
of OG killing, kill curves were used in addition to MCCs (Fig.
2). Organisms cultured on fresh media as described above were
suspended in ACES buffer to a McFarland density of 1.0. 3-OG
at, below, and above the MCC was prepared as a 10-fold excess
solution in the appropriate buffer. Experiments were initiated
by the addition of 1/10 volume of 3-OG to the bacterial suspensions
and mixing with a vortex mixer. Samples were taken at various
times and diluted into 5% HSA containing ACES buffer (HSA binds
the OG and stops killing), and serial 10-fold dilutions were
prepared and plated in triplicate on the appropriate medium
and used to determine the concentration of bacteria at each
time point. The number of organisms was determined at time zero
from the starting bacterial suspension. The suspension was incubated
along with a suspension containing the drug and sampled at 5
min. If the bacterial concentrations differed at the two times,
the experiment was rejected. Values of CFU per ml were determined
from plates containing between 30 and 300 colonies per plate.
The data were used to construct survival curves as log
10 CFU/ml
versus time of exposure. Decimal reduction times (
D values)
were calculated using the linear portion of the graph (using
linear regression) as
D = –1/slope of the graph of log
10 CFU/ml versus time (
1,
2,
7,
9,
10) and by inspection. 3-OG
rapidly kills test organisms at or above the MCC for the organism,
with
D values typically of about 1 min. Little killing was observed
below the MCC. As currently defined, the MCC for an organism
and drug represents the concentration where the
D value is less
than 8 min. Combining both methods easily defines the important
parameters of microbicides.
OG inactivated STI pathogens at concentrations lower than those
required to kill vaginal lactobacilli, supporting its use as
a vaginal microbicide. Use of 1-OG and 3-OG resulted in comparable
MCCs. HSA appears to bind the fatty acid moiety of OG, resulting
in protection of bacteria until the molar ratio of OG to HSA
exceeds 6 plus the MCC, at which point the pathogens are typically
inactivated.

ACKNOWLEDGMENTS
This work was supported by grants 6PO1 AI39061 and 5U19 A1051
661-05 from the National Institutes of Health.

FOOTNOTES
* Corresponding author. Mailing address: Room 520, Magee-Womens Research Institute, 204 Craft Avenue, Pittsburgh, PA 15213-3180. Phone: (412) 641-6025. Fax: (412) 641-5290. E-mail:
bjm4{at}pitt.edu 
Published ahead of print on 28 January 2008. 

REFERENCES
1 - Bruch, M. K. 1991. Methods of testing antiseptics: antimicrobials used topically in humans and procedures for hand scrubs, p. 1028-1068. In S. S. Block (ed.), Disinfection, sterilization, and preservation, 4th ed. Lea & Febiger, Philadelphia, PA.
2 - Canton, E., J. Peman, M. Sastre, M. Romero, and A. Espinel-Ingroff. 2006. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob. Agents Chemother. 50:2829-2832.[Abstract/Free Full Text]
3 - Gupta, P., R. Deena, B. K. Patterson, L. Caruso, K. Kathy, L. C. Rohan, M. A. Parniak, C. E. Isaacs, and S. L. Hillier. 2006. Use of frozen-thawed cervical tissues in the organ culture system to measure anti-HIV activities of candidate microbicides. AIDS Res. Hum. Retrovir. 22:419-424.[CrossRef][Medline]
4 - Isaacs, C. E., and M. F. Lampe. 2000. Lactolipids, p. 159-182. In A. S. Naidu (ed.), Natural food antimicrobial systems. CRC Press, Boca Raton, FL.
5 - Isaacs, C. E., J. H. Jia, and W. Xu. 2004. A lipid-peptide microbicide inactivates herpes simplex virus. Antimicrob. Agents Chemother. 48:3182-3184.[Abstract/Free Full Text]
6 - Lampe, M. F., L. M. Ballweber, C. E. Isaacs, D. L. Patton, and W. E. Stamm. 1998. Killing of Chlamydia trachomatis by novel antimicrobial lipids adapted from compounds in human breast milk. Antimicrob. Agents Chemother. 42:1239-1244.[Abstract/Free Full Text]
7 - Mazzola, P. G., T. C. Penna, and A. M. Martins. 2003. Determination of decimal reduction time (D value) of chemical agents used in hospitals for disinfection purposes. BMC Infect. Dis. 3:24.[CrossRef][Medline]
8 - Moncla, B. J., and S. L. Hillier. 2005. Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex. Transm. Dis. 32:491-494.[CrossRef][Medline]
9 - Prince, H. N., D. L. Prince, and R. N. Prince. 1991. The principles of viral control and transmission, p. 411-443. In S. S. Block (ed.), Disinfection, sterilization and preservation, 4th ed. Lea & Febiger, Philadelphia, PA.
10 - Wickramanayake, G. B., and J. Sproul. 1991. Kinetics of the inactivation of microorganisms, p. 72-84. In S. S. Block (ed.), Disinfection, sterilization, and preservation, 4th ed. Lea & Febieger, Philadelphia, PA.
Antimicrobial Agents and Chemotherapy, April 2008, p. 1577-1579, Vol. 52, No. 4
0066-4804/08/$08.00+0 doi:10.1128/AAC.01023-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Skinner, M. C., Stamm, W. E., Lampe, M. L.
(2009). Chlamydia trachomatis Laboratory Strains versus Recent Clinical Isolates: Implications for Routine Microbicide Testing. Antimicrob. Agents Chemother.
53: 1482-1489
[Abstract]
[Full Text]